文献速递肾移植

碱治疗对肾移植受者血管功能安全性与疗效的初步研究

A Pilot Study of the Safety and Efficacy of Alkali Therapy on Vascular Function in Kidney Transplant Recipients.
PubMed 文献 · Kidney Int Rep · 2021-06-24

本研究为18周随机双盲安慰剂对照交叉初步试验,纳入20例移植至少1年、eGFR≥45 ml/min/1.73 m2且血清碳酸氢盐20-26 mEq/L的成人肾移植受者,比较碳酸氢钠与安慰剂对血管功能的影响。主要结局为肱动脉血流介导扩张(FMD)变化,碳酸氢钠治疗8周后FMD较安慰剂无显著增加(平均变化2.2%,95%CI -0.1至4.6,P=0.06)。碳酸氢钠治疗安全可行,未加重血压、体重或低钾血症,但需更大规模随机对照试验验证。

要点

  • 碳酸氢钠治疗未显著改善肾移植受者的血管内皮功能(FMD变化P=0.06)。
  • 碳酸氢钠治疗安全,未导致血压恶化、体重增加或低钾血症。
  • 碳酸氢钠治疗使尿铵排泄减少9 mmol/d(P=0.003)。

核心结论

  • 碳酸氢钠治疗在肾移植受者中安全可行,但未显著增加血流介导扩张(FMD)。
  • 结果支持需开展更大规模随机对照试验进一步验证。

研究设计与样本

  • 18周随机双盲安慰剂对照交叉初步试验,纳入20例成人肾移植受者。
  • 纳入标准:移植至少1年,eGFR≥45 ml/min/1.73 m2,血清碳酸氢盐20-26 mEq/L。
  • 每治疗期8周,期间洗脱期2周。

主要发现

  • 20例患者完成研究并纳入主要分析,基线平均(SD)eGFR为75(22)ml/min/1.73 m2。
  • 碳酸氢钠治疗8周后FMD较安慰剂无显著增加(平均变化2.2%,95%CI -0.1至4.6,P=0.06)。
  • 血清碳酸氢盐水平未显著升高(0.3 [1.5] mEq/L,P=0.37)。
  • 碳酸氢钠治疗使尿铵排泄减少9 mmol/d(P=0.003)。
  • 高敏C反应蛋白、白介素-6、eGFR或尿白蛋白肌酐比无显著变化。

临床怎么用

  • 对于eGFR≥45 ml/min/1.73 m2且血清碳酸氢盐20-26 mEq/L的稳定期肾移植受者,碳酸氢钠治疗未显示血管功能获益。
  • 碳酸氢钠治疗未引起血压恶化、体重增加或低钾血症,安全性可接受。

局限性

  • 本研究为初步试验,样本量小(20例),可能不足以检测FMD的显著差异。
  • 研究人群限于eGFR≥45 ml/min/1.73 m2且血清碳酸氢盐20-26 mEq/L的肾移植受者,结果外推受限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Metabolic acidosis is associated with cardiovascular events, graft function, and mortality in kidney transplant recipients (KTRs). We examined the effect of alkali therapy on vascular endothelial function in KTRs. METHODS: We performed an 18-week, randomized, double-blind, placebo-controlled crossover pilot study examining the effect of sodium bicarbonate therapy versus placebo on vascular function in 20 adult KTRs at least 1 year from transplant with an estimated glomerular filtration rate (eGFR) ≥45 ml/min per 1.73 m2 and a serum bicarbonate level of 20 to 26 mEq/L. Each treatment period was 8 weeks in duration with a 2-week washout period between treatments. The primary outcome was change in brachial artery flow-mediated dilation (FMD) between sodium bicarbonate treatment and placebo. RESULTS: Twenty patients completed the study and were included in the primary analysis. The mean (SD) baseline eGFR of participants was 75 (22) ml/min per 1.73 m2, respectively. Serum bicarbonate levels did not increase significantly with treatment (0.3 [1.5] mEq/L, P = 0.37). Sodium bicarbonate therapy was not associated with worsening blood pressure, weight gain, or hypokalemia. There was no significant increase in FMD after 8 weeks of sodium bicarbonate therapy compared to placebo (mean change in FMD 2.2%, 95% CI -0.1 to 4.6, P = 0.06). There were no significant changes in high-sensitivity C-reactive protein, interleukin-6, eGFR, or urinary albumin-to-creatinine ratio during treatment. Urinary ammonium excretion decreased by 9 mmol/d (P=0.003), with sodium bicarbonate. CONCLUSIONS: Sodium bicarbonate therapy is safe and feasible in KTRs, and our results strengthen the need for a larger randomized controlled trial.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Bohling R, Grafals M, Moreau K, et al. A Pilot Study of the Safety and Efficacy of Alkali Therapy on Vascular Function in Kidney Transplant Recipients. Kidney Int Rep. 2021. PMID: 34514193. doi:10.1016/j.ekir.2021.06.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。